SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins sharp pullback below a major psychological level is driving discussion, with traders pointing to forced liquidations, ETF outflows and broader market weakness as possible pressures. Sentiment is divided between calls for a deeper correction and claims that the dip is a bear trap or buying opportunity.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is drawing attention over founder and executive departures alongside concerns about oncology pipeline execution, including BNT113 missing its progression-free-survival endpoint while overall-survival follow-up continues. Traders debate whether leadership uncertainty and declining COVID-vaccine business outweigh the companys other cancer programs and upcoming clinical catalysts.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstops steep selloff and repeated 52-week lows are drawing attention amid concerns about weakening restaurant traffic, pressured consumer spending, and declining same-store sales. Traders are split between calling the decline an oversold buying opportunity, citing franchise growth, and expecting further downside as the consumer and restaurant-sector headwinds persist.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubriks strong Q2 results and raised outlook have fueled renewed interest, though the shares initially sold off as traders questioned the slower cloud net-new ARR outlook and managements guidance. The rebound is also being attributed to cybersecurity-sector momentum and AI-related security demand, while bears continue to flag valuation and relative underperformance concerns.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Bitcoins sharp swingsfrom liquidation-driven selling to a strong reboundare driving attention, with traders debating whether the bounce marks renewed momentum or a temporary squeeze. ETF demand and hopes for clearer U.S. crypto rules are cited as supportive, while bearish voices point to macro risks and lingering downside concerns.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axons proposed $1 billion convertible-note offering triggered selling on concerns about potential shareholder dilution, though some traders view the financing as growth capital and the pullback as a buying opportunity. The discussion also reflects volatility ahead of earnings, with bulls emphasizing growth prospects and bears citing the stocks high valuation and margin concerns.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRPs continued weakness and stagnation amid a broader crypto pullback dominate the discussion, with traders watching support and debating whether Bitcoin-led selling is driving further downside. Frustrated holders point to token supply, Ripples escrow sales and stablecoin competition as reasons gains may remain limited, while bullish traders view the decline as a buying opportunity and cite potential adoption catalysts.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck and Modernas Phase 3 melanoma-vaccine results with Keytruda dominate discussion: the combination reduced recurrence or death risk, but the stock reaction was mixed as some traders viewed the data as positive while others said it fell short of elevated expectations. Traders also debate whether the partnership can add to Mercks oncology growth amid Keytruda patent-cliff concerns.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is drawing attention after a sharp pullback that traders say is tracking weakness in Bitcoin and the broader crypto market, with the coin giving back recent gains. The discussion is split between dip-buyers and long-term bulls and traders calling for further downside, while many focus on whether support will hold.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

Reports of a possible AstraZenecaBristol Myers Squibb merger have fueled debate over the scale, financing and strategic merits of a tie-up; traders also reacted to a subsequent report that no discussions had taken place, which cooled the speculation. The merger remains unconfirmed, and the community is divided between seeing a potential growth opportunity and viewing a deal as costly and disruptive.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares

Equity

Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.


Jordi Visser’s 20-Year Bombshell Prediction Includes ‘Religion, Gold, And Now Bitcoin’

Cryptocurrency

Visser said that crypto's real customer hasn't arrived yet, adding that "Crypto is not made for humans," naming AI agents as the real demand.


‘Pure Chartists Think It’s Over, I Don’t’ – Influential Macro Strategist Pushes Back On Bear Market Narrative

The Treasury General Account balance has declined, indicating that the government is bringing capital back into the markets, despite the tiny decline.


Bearish Sentiment

<ul class="summary-bullets"><li>Wood trimmed major recent winners, selling about $18 million of TWST along with smaller positions in TXG and CDNA.</li><li>RXRX has a 12-month consensus price target of $7.22, according to Koyfin, implying an upside potential of more than 51% from current levels.</li><li>Intellia is awaiting FDA review of its lead therapy for hereditary angioedema, with PDUFA date on March 10, 2027.</li></ul>Cathie Wood’s ARK Invest reshuffled its biotech holdings, buying several stocks that posted strong gains on Monday while trimming some of the sector’s biggest recent winners.Across&nbsp;<a href="https://stocktwits.com/symbol/ARKG">ARK Genomic Revolution ETF (ARKG)</a> and flagship&nbsp;<a href="https://stocktwits.com/symbol/ARKK">ARK Innovation ETF (ARKK)</a>, Wood bought about 1.48 million shares of Recursion Pharmaceuticals (RXRX), 96,308 shares of Intellia Therapeutics (NTLA), and 115,472 shares of Veracyte (VCYT), worth about $6.1 million, $1.2 million, and $5.3 million, respectively.Meanwhile, ARK sold 90,713 Twist Bioscience (TWST) shares worth $18 million, alongside smaller sales of 10x Genomics (TXG) and CareDx (CDNA).<h2 class="st-heading-2">What RXRX, NTLA And VCYT Have On Offer</h2><a href="https://stocktwits.com/symbol/RXRX">RXRX shares</a> surged more than 16% on Monday, and while there was no immediate trigger for the move, the AI drug-discovery company recently extended its data-licensing partnership with Tempus through 2029.The stock has a 12-month consensus price target of $7.22, according to Koyfin, implying an upside potential of more than 51% from current levels.<a href="https://stocktwits.com/symbol/NTLA">NTLA shares</a> closed 4% higher in the previous session, but the stock is currently down 2%. Intellia is awaiting U.S. Food and Drug Administration (FDA) review of its lead therapy for hereditary angioedema, with March 10, 2027, penciled in as the decision date.While NTLA shares have seen strong buying interest so far this year, surging more than 38%, Barclays believes the stock is likely to see a significant selloff. The firm initiated coverage with an ‘Underweight’ rating and an $8 price target, implying a 36% downside from current levels.Wood continued to build her <a href="https://stocktwits.com/symbol/VCYT">VCYT</a> position after adding roughly 159,000 shares earlier this month. Late last month, Veracyte said Phase 3 data showed its Decipher Prostate test could help identify which intermediate-risk prostate cancer patients may benefit from adding hormone therapy to radiation.According to Street estimates, the stock could climb at least 21% from current levels.&nbsp;&nbsp;<h2 class="st-heading-2">ARK Sells TWST, TXG, CDNA Despite Massive Moves</h2>ARK continued to unload <a class="mention" data-mention="$TWST" data-symbol-id="TWST" href="https://stocktwits.com/symbol/TWST" target="_blank">TWST shares</a> despite a sharp rally over the past month. TWST surged 8.7% on Monday and has added more than 60% to its value over the past month amid momentum around its synthetic-DNA platform and its agreement to support Eli Lilly’s TuneLab AI drug-discovery platform. Over the past few weeks, ARKG has unloaded TWST shares worth around $6 million.Meanwhile, TXG shares, which climbed 4.5% on Monday, have surged more than 48% in the past month, while <a href="https://stocktwits.com/symbol/CDNA">CDNA rose</a> 4% to its highest level in more than four years on Monday.<h2 class="st-heading-2">Retail’s Take On ARK’s Biotech Portfolio</h2>Retail sentiment on Stocktwits was bullish for TXG, NTLA, CDNA, and RXRX, bearish for VCYT, and neutral for TWST.<img src="https://news.stocktwits-cdn.com/ARK_YTD_8c95bdf841.png" alt="ARK YTD.png">Twist Bioscience and 10x Genomics have been the standout performers so far this year, up about 533% and 499%, respectively, while CareDx has gained roughly 265%, and NTLA, RXRX, and VCYT have posted double-digit advances.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/redwire-ceo-sees-massive-space-infrastructure-growth-ahead-compares-orbital-data-center-boom-to-rise-of-satellite-tv/cZDtb7wRBkY">Redwire CEO Sees ‘Massive’ Space Infrastructure Growth Ahead – Compares Orbital Data Center Boom To Rise Of Satellite TV</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cathie Wood, CEO & Chief Investment Officer of ARK Invest, speaks onstage during Day 2 of 2023 Invest Fest at Georgia World Congress Center on August 27, 2023 in Atlanta, Georgia. (Photo by Paras Griffin/Getty Images)

Cathie Wood’s ARK Invest reshuffled its biotech holdings, buying several stocks that posted strong gains on Monday while trimming some of the sector’s biggest recent winners.

BlackRock Senior High Income Fund, Inc.

ARK Investment Management LLC - ARK Genomic Revolution ETF

Caredx Inc

Intellia Therapeutics Inc

Recursion Pharmaceuticals Inc

Twist Bioscience Corp

10x Genomics Inc - Ordinary Shares - Class A

Veracyte Inc

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Fundamentals

Info

ARK BlackRock Senior High Income Fund, Inc.

Latest ARK News